| Name | Title | Contact Details |
|---|---|---|
Scott Cross |
Senior Application Architect, CISO | Profile |
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Cobalt Sports Holdings was created to provide support, opportunities, collaboration and revenue streams to sports programs by combining the strength in numbers philosophy with clubs that are independent by structure and desire. These are sports programs that want to: Remain independent yet want to build programs that can retain players and coaches Compete at the highest levels Create exposure for players Be relevant at the local, state and national level events Continue to grow within their community. At Cobalt, we believe that EVERY club and EVERY player is relevant. That EVERY club deserves to thrive and that EVERY player should have multiple pathways as well as high-level coaching education opportunities. Pathways to the pros and pathways to college soccer. By combining like minded leaders running independent programs, a superior community of offerings is available to our members.
For more than a quarter of a century, Specialty Lighting Group has provided quality lighting products and design services for a variety of national clients. We create lasting value by offering a big companys expertise and resources with a small companys attention to service and detail. Be it a retail location or restaurant, we generate computerized lighting layouts and assist your designer or architect to ensure the lighting is appropriate for the application, energy-efficient, and available to meet your schedule. We also provide energy audits to assess the efficiency of your current lighting setup and figure out what utility rebates your company may be entitled to. Additionally, we provide a plan to increase the efficiency of your lighting and attempt to garner the greatest amount of utility rebates possible to save not only energy, but your money as well. With our large list of lighting and lamp vendors, we guarantee that we can provide you the perfect fixture or lamp for your project and our large inventory ensures that your lighting will arrive on time, no matter how tight your schedule may be. To find out more about Specialty Lighting Group, visit our website at www.sslighting.com, or watch the following video: http://sslighting.com/Images/specialty_lighting_wb.swf
Premia Managing Agency Limited ("PMAL") provides risk-transfer and run-off solutions for other Lloyds syndicates and capital providers. It is responsible for managing the run-off of Syndicate 1884 for the Year of Account 2018, following cessation of live market underwriting on 31 December 2018. PMAL is a subsidiary of Premia Holdings Ltd, a Bermuda based legacy reinsurance group with operations in the USA, Bermuda, UK and EU. PMAL is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority.